Mark Schoenberg Sells 5,149 Shares of Urogen Pharma (NASDAQ:URGN) Stock

Key Points

• Mark Schoenberg, an insider at Urogen Pharma, sold 5,149 shares at an average price of $19.14, totaling $98,551.86, reducing his ownership by 3.15% to 158,229 shares.
• Urogen Pharma's stock recently gained 1.7%, reaching $19.22, with significant trading volume of 1,159,647 shares.
• Analysts maintain a consensus rating of "Buy" for Urogen Pharma, with target prices ranging from $25.00 to $50.00.

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 5,149 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $98,551.86. Following the sale, the insider owned 158,229 shares in the company, valued at $3,028,503.06. The trade was a 3.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 9th, Mark Schoenberg sold 5,162 shares of Urogen Pharma stock. The shares were sold at an average price of $7.37, for a total transaction of $38,043.94.

Urogen Pharma Stock Performance

URGN traded up $0.34 during trading hours on Friday, reaching $19.40. The company's stock had a trading volume of 1,007,990 shares, compared to its average volume of 1,235,309. The company's 50-day moving average is $12.52 and its 200-day moving average is $11.02. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $19.74. The firm has a market cap of $896.28 million, a PE ratio of -6.10 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to the consensus estimate of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. Equities analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Institutional Trading of Urogen Pharma

Several institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in shares of Urogen Pharma in the fourth quarter valued at about $1,472,000. Lazard Asset Management LLC acquired a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $67,000. Janus Henderson Group PLC bought a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $149,000. ProShare Advisors LLC bought a new stake in shares of Urogen Pharma in the fourth quarter valued at approximately $137,000. Finally, Rhumbline Advisers grew its position in Urogen Pharma by 4.3% during the first quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock worth $591,000 after buying an additional 2,196 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on URGN shares. Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a "buy" rating in a research report on Friday, June 13th. Guggenheim reissued a "buy" rating and issued a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a research note on Friday, June 13th. Scotiabank reaffirmed an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. The Goldman Sachs Group set a $16.00 target price on shares of Urogen Pharma and gave the stock a "neutral" rating in a report on Friday, June 13th. Finally, D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Urogen Pharma in a report on Monday, July 7th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $32.86.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.